Br J Haematol September 2020 PMID 32645204

Double-bright (CD56bright/CD16bright) natural killer cell adoptive immunotherapy for SARS-CoV-2.

Lúcia Silla

Full text PDF Download social card

Mentions

Peak: 2 in Jul 2020

across 2 sources since Jul 2020

Extended reach

34,595

potential audience

Total likes

Video views

158

Mentions per month

Jul 2020 – Sep 2020

Where it's discussed

X / Twitter4 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions demonstrate a positive outlook on the research, with mentions of articles and webinars like the 'Immunotherapy with natural killer cells' webinar and references to recent publications, highlighting a general interest without deep technical debate, emphasizing the emerging importance of NK cell therapy in COVID-19 treatment.

AgreementModerate agreement

Most discussions express support or positive recognition of the potential benefits of the immunotherapy approach, showing general agreement with the publication's significance.

InterestModerate interest

The posts indicate moderate interest, highlighted by mentions of webinars and articles discussing NK cell therapy, but lack in-depth technical engagement.

EngagementModerate engagement

Comments reference related media such as webinars and articles, suggesting some level of fuller engagement with the topic, but not necessarily deep analytical discussion.

ImpactModerate impact

The overall tone suggests recognition of the therapy's potential importance, with references to new publications and webinars implying perceived impact on COVID-19 treatment research.

Abstract in brief

The text discusses a type of immunotherapy using natural killer (NK) cells, specifically CD56bright and CD16bright subsets, to treat SARS-CoV-2 (COVID-19).
It suggests that these NK cells could be a potential treatment approach by enhancing the body's ability to fight the virus.
The focus is on the adoptive transfer of these immune cells as a therapeutic strategy against COVID-19.]

Read the full abstract

All mentions

Natural Killer Cell Immunotherapy for COVID-19 Treatment Progress

The series Conexes TMO presents a webinar on natural killer cell immunotherapy as a novel approach during the COVID-19 pandemic. Dr. Lucia Silla discusses recent advances, the role of NK cells against SARS-CoV-2, and…

SBTMO · Aug 12, 2020 158 views

BSH - Haematology

@BritSocHaem · X

New BJH correspondence: Double‐bright (CD56bright/CD16bright) natural killer cell adoptive immunotherapy for SARS‐CoV‐2. https://t.co/pC8h1B3Btw

Sep 2, 2020 · 1 like · 1 share · 16,103 followers View post →

SBTMO

@SBTMO · X

Aug 13, 2020 · 3 likes · 946 followers View post →

BSH - Haematology

@BritSocHaem · X

New BJHaem article: Double‐bright (CD56bright/CD16bright) NK cell adoptive immunotherapy for SARS‐CoV‐2 https://t.co/wAZerGdfya

Jul 17, 2020 · 1 like · 16,103 followers View post →

NK papers

@NK_papers · X

Double-bright (CD56bright/CD16bright) NK cell adoptive immunotherapy for SARS-CoV-2. by Silla L https://t.co/0WWAMXNKTl

Jul 10, 2020 · 1,284 followers View post →